NB002

NB002 is a novel and fully humanized Tim-3 blocking antibody differentiates from its competitors in function and epitope recognition. Its unique feature of restoring both innate and adaptive immune function provides novel treatment options in neo-adjuvant settings.

NB002 is an innovative humanized (IgG1κ) Fc-engineered antibody developed through NeologicsBio's integrated target validation and antibody screening Tier-A platform. NB002 exhibits selective binding to TIM3 in the low nanomolar (nM) range, and functions as an antagonist as demonstrated by reporter and primary cell-based assays. The antibody proves its potential by increasing IFNγ secretion in activated PBMCs and enhancing NK cell effector function. Furthermore, NB002 exhibited a distinctive activity of restoring immune cell functions, including antigen presentation and exhibited superior efficacy in multiple humanized murine models of cancer as monotherapy. Importantly, X-ray crystallography reveals that NB002 recognizes a unique epitope, which has been confirmed through epitope binning and structural alignment, setting it apart from competitors in both function and epitope recognition. These novel features of restoring acquired and innate immune function provides promising treatment options in the neoadjuvant setting, either as stand alone or in combination with existing therapies.

View Poster Presentation AACR Annual Meeting 2023

Click to expand